IDEAYA Biosciences (IDYA) said Wednesday it has submitted an investigational new drug application to the US Food and Drug Administration for IDE574, a potential therapy for lung and breast cancer.
The company said it is planning to begin a phase 1 dose escalation trial of the drug as a monotherapy in Q1 2026.
The company said that preclinical studies to be published in H1 2026 show the potential therapy can target key enzymes in certain tumors to result in "robust anti-tumor activity" in lung and breast cancer models.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments